ARS Pharmaceuticals (SPRY) news

Archtis - Partnership addresses gap for defense organizations under multinational classification regimes

archTIS Limited (ASX:AR9, OTCQB:ARHLF) has developed a suite of data-centric security solutions tailored to address the unique challenges faced by defense organizations operating under multinational classification regimes. These solutions leverage attribute-based access control (ABAC) and zero…

Hays 1Q total comp net fees -3%

Hays: Sept. net fee growth rate was ~2 %

Hays, a global professional services firm, reported net fee growth rate of approximately 2% in September 2026. This figure reflects the company’s performance in the period and provides insight into its ongoing business momentum. The growth rate, while modest, aligns with broader market trends and…

SPPyre Therapeutics is said to offer shares at $85 each

SPPyre Therapeutics has announced an initial public offering (IPO) in which shares are being offered at $85 each. The company, which focuses on developing novel therapies for rare diseases, has drawn attention from investors due to its recent clinical trial results and strong financial backing from…

ALK-Abello A/S - Agreement does not affect Alk's 2026 financial guidance or long-term targets

ALK-Abelló A/S has confirmed that a recent agreement will not impact its 2026 financial guidance or long-term strategic targets. The company made the statement following the release of its second-quarter 2026 earnings call transcript, which indicated continued alignment with financial expectations…